Shining a Light on HER2-Low and HER2-Ultralow Metastatic Breast Cancer: A Pathologist’s Guide to Bridging the Diagnostic Gaps

Learn to score HER2 levels via immunohistochemistry in both routine and complex breast cancer cases, identify patients who may benefit from HER2-targeted therapy, and select novel therapies for treatment of HER2-low or HER2-ultralow metastatic breast cancer by attending a live, on-demand webcast and reviewing an expert-written commentary and downloadable slides.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.